Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Colon Cancer
Clarient Launches New Colorectal Cancer Test
July 15th, 2008
Clarient, Inc. (NASDAQ:CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists, and the pharmaceutical industry, announced its new offering, KRAS, which has been validated as a laboratory-developed test to be used as a predictive molecular biomarker for patients with colorectal cancer (CRC). The importance of KRAS testing was recently reported at this year's ASCO meeting in Chicago and is supported by data published in the Journal of Clinical Oncology (JCO) in April 2008. Ron Andrews, Clarient's Chief Executive Officer said, "Identifying the KRAS mutation can help individual patients and their physicians understand the...
Source: Cancer Weekly (2008-07-15)
|
